Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Indonesia pauses distribution of a batch of AstraZeneca vaccine

05/16/2021 | 03:22am EDT

JAKARTA, May 16 (Reuters) - Indonesia has suspended distribution of a batch of AstraZeneca's coronavirus vaccine to run tests for sterility and toxicity following the death of a 22-year-old man a day after immunisation, the health ministry said on Sunday.

The "CTMAV547" batch consists of 448,480 vaccine doses that arrived in the Southeast Asian nation last month - part of a delivery of more than 3.85 million doses from the COVAX Facility, backed by the World Health Organization.

Some of the doses have been distributed in the capital city Jakarta and the province of North Sulawesi, as well as given to the military, the ministry said in a statement.

A national committee in charge of monitoring the effects of novel coronavirus vaccination launched an investigation earlier this month after a 22-year-old man in Jakarta died a day after receiving an AstraZeneca shot.

The man received his dose from the CTMAV547 batch, health ministry spokeswoman Siti Nadia Tarmizi told Reuters.

"This is a form of caution by the government to ensure the safety of this vaccine," she said in a statement, adding that distribution of other batches of AstraZeneca vaccines will not be affected.

The batch test could take at least two weeks, said the head of the vaccine monitoring committee, Hindra Irawan Satari.

"After it is proven that it is sterile and does not contain toxins, the use of the vaccine will be resumed. The fastest we can get the results will be in two weeks," he said.

AstraZeneca Indonesia said it "respects" the government's decision about the temporary suspension.

"We share the government's value that patient safety is the highest priority and AstraZeneca has robust processes in place for the collection, analysis, and reporting of adverse events," it said in the statement.

Since the start of the pandemic early last year, Indonesia has recorded around 1.74 million cases of infection of the novel coronavirus that causes the potentially fatal COVID-19 respiratory disease. The country's death toll stands at 48,093 as of Sunday.

The government has been pushing to accelerate its vaccination programme to control the spread of the virus. Official data showed that as of Sunday, nearly 9 million people have been fully vaccinated. (Writing by Fransiska Nangoy; Editing by Clarence Fernandez, Christopher Cushing, William Maclean)

© Reuters 2021
All news about ASTRAZENECA PLC
02:38pDual-antibody drugs effective against COVID-19 variants in animal study
12:33pMODERNA  : U.S. directs millions of COVID-19 shots to Latin America, Africa, Asi..
10:43aBionity - Mix-and-match vaccines generate a particularly strong immune respon..
07:45aASTRAZENECA  : GSK to boost spending power of pharma business post break-up
06:21aASTRAZENECA  : Thailand Seeks to Offset Rollout Delays with AstraZeneca COVID-19..
04:55aIndia Starts Free AstraZeneca, Bharat Biotech COVID-19 Jabs for Adults
04:35aASTRAZENECA  : welcomes Court ruling on supply of its COVID-19 vaccine to Europe
04:04aASTRAZENECA  : India's vaccinations hit record with free COVID shots
04:04aASTRAZENECA  : India's vaccinations hit record with free COVID shots
01:57aWhat you need to know about the coronavirus right now
More news
Financials (USD)
Sales 2021 30 966 M - -
Net income 2021 4 588 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 36,2x
Yield 2021 2,46%
Capitalization 152 B 154 B -
EV / Sales 2021 5,27x
EV / Sales 2022 4,50x
Nbr of Employees 76 100
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 132,64 $
Last Close Price 115,73 $
Spread / Highest target 47,7%
Spread / Average Target 14,6%
Spread / Lowest Target -16,8%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC14.47%151 865
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.5.57%199 795